Skip to main content
Log in

Re: Risk factors and predictors of treatment responses and complications in immune thrombocytopenia

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Neunert C, Terrell DR, Arnold DM et al (2019) American Society of Hematology 2019 guidelines for immune thrombocytopenia [published correction appears in Blood Adv. 2020 Jan 28;4(2):252]. Blood Adv 3(23):3829–3866

    Article  CAS  Google Scholar 

  2. Ong SY, Tan CW, Ramya V, Malik AA, Lee XH, Hwang JCC, Yang Y, Ng HJ, Lee LH (2021) Risk factors and predictors of treatment responses and complications in immune thrombocytopenia. Ann Hematol. https://doi.org/10.1007/s00277-021-04424-z

  3. Mishra K, Malhotra P, Jandial A, Kumar LD, Varma N, Dhiman RK, Yanamandra U et al (2017) Bleeding risk assessment by sonoclot in severe immune thrombocytopenia. Blood 130(Suppl 1):2320

    Google Scholar 

  4. Mishra K, Jandial A, Sandal R, Porchezhian P, Charan S, Lad D et al Poor platelet function on sonoclot signature is associated with high incidence of bleeding in severe immune thrombocytopenia. Blood 132(Suppl 1):4491. https://doi.org/10.1182/blood-2018-99-117086

  5. Mishra K, Kumar S, Jandial A, Sahu KK, Sandal R, Ahuja A et al (2020 (accepted) Real-world experience of rituximab in immune thrombocytopenia. Indian J Hematol Blood Transfus 10.1007/s12288-020-01351-3

  6. Mishra K, Pramanik S, Jandial A, Sahu KK, Sandal R, Ahuja A et al (2020) Real-world experience of eltrombopag in immune thrombocytopenia. Am J Blood Res. 10(5):240–251

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Sahu KK, Varma SC (2015) Cortical vein thrombosis in a case of idiopathic thrombocytopenic purpura. Platelets. 26(4):374–5

    Article  CAS  Google Scholar 

  8. Wong RSM, Saleh MN, Khelif A, Salama A, Por-tella MSO, Burgess P, Bussel JB (2017) Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood 130:2527–2536

    Article  CAS  Google Scholar 

  9. Kim YK, Lee SS, Jeong SH, Ahn JS, Yang DH, Lee JJ, Kim HJ (2015) Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia. Blood Res 50:19–25

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

All authors have seen the manuscript and agree to the content and data. All the authors played a significant role in the paper

Corresponding author

Correspondence to Kamal Kant Sahu.

Ethics declarations

Ethical approval

The article does not contain the participation of any human being and animal.

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mishra, K., Sahu, K.K. Re: Risk factors and predictors of treatment responses and complications in immune thrombocytopenia. Ann Hematol 101, 447–448 (2022). https://doi.org/10.1007/s00277-021-04476-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-021-04476-1

Navigation